Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives

Banerjee, Antara; Pathak, Surajit; Subramanium, Vimala Devi; Gunasekaran, Dharanivasan; Murugesan, Ramachandran; Verma, Rama Shanker

doi:10.1016/j.drudis.2017.05.006

Cited by 188 publications

(94 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Although much progress has been made in surgical and complementary therapy of COAD in recent years, the prognosis of patients with COAD is still poor. 3 The main reason is that the pathogenesis of COAD is complex. Most patients are in the advanced stage at the time of diagnosis, losing the opportunity of surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD</p>

Lu¹,

Wu²,

Cui³

et al. 2020

OTT

View full text Add to dashboard Cite

This study aims to systematically analyze multi-omics data to explore new prognosis biomarkers in colon adenocarcinoma (COAD). Materials and Methods: Multi-omics data of COAD and clinical information were obtained from The Cancer Genome Atlas (TCGA). Univariate Cox analysis was used to select genes which significantly related to the overall survival. GISTIC 2.0 software was used to identify significant amplification or deletion. Mutsig 2.0 software was used to identify significant mutation genes. The 9-gene signature was screened by random forest algorithm and Cox regression analysis. GSE17538 dataset was used as an external dataset to verify the predictive ability of 9-gene signature. qPCR was used to detect the expression of 9 genes in clinical specimens. Results: A total of 71 candidate genes are obtained by integrating genomic variation, mutation and prognostic data. Then, 9-gene signature was established, which includes HOXD12, RNF25, CBLN3, DOCK3, DNAJB13, PYGO2, CTNNA1, PTPRK, and NAT1. The 9-gene signature is an independent prognostic risk factor for COAD patients. In addition, the signature shows good predicting performance and clinical practicality in training set, testing set and external verification set. The results of qPCR based on clinical samples showed that the expression of HOXD12, RNF25, CBLN3, DOCK3, DNAJB13, and PYGO2 was increased in colon cancer tissues and the expression of CTNNA1, PTPRK, NAT1 was decreased in colon cancer tissues. Conclusion: In this study, 9-gene signature is constructed as a new prognostic marker to predict the survival of COAD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD</p>

Lu¹,

Wu²,

Cui³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…Colon cancer is recorded as the third cancer that causes the death in the world (Banerjee et al 2017 ). There are three main ways for treating this cancer type: surgery, chemotherapy and radiation.…”

Section: Introductionmentioning

confidence: 99%

Different zeolite systems for colon cancer therapy: monitoring of ion release, cytotoxicity and drug release behavior

et al. 2019

View full text Add to dashboard Cite

Three types of oral administrated micronized zeolites [ZSM-5, zeolite A and Faujasite NaX (ZSM-5, ZA and ZX, respectively)] were prepared as anticancer 5-fluorouracil (5-Fu) delivery systems for colon cancer treatment. They were prepared by economically widespread and cheap natural resource, kaolin, at low temperatures, using microwave advanced tool. The obtained powders were characterized by XRD, SEM/EDX and BET; meanwhile, their degradation was investigated in two gastric fluids; FaSSGF (pH 1.6) and FeSSGF (pH 5), through concentration measurement of their solution disintegrated elemental constituents of Na + , Al 3+ and Si 4+ ions. Also, the processes of drug release and mechanism in both solutions were investigated. Moreover, the inhibition action of 5-Fu-free and 5-Fu-conjugated zeolites on colon cancer cells (CaCo-2) was estimated. The results showed that, the prepared zeolites possessed high surface areas of 526, 250, and 578 m 2 /g for ZSM-5, ZA and ZX, respectively. Although, zeolite structures seemed significantly stable, their frameworks seemed more likely reactive with time. The ions and drug release for zeolites occurred in successively two stages and found to be pH dependent, where the drug and zeolite ions were significantly of higher values in the more acidic media of the gastric solution (pH 1.6) than those of the mild acidic one (pH 5). The obtained activity indicated no cytotoxic affinity for all the prepared zeolite types. Accordingly, the synthesized zeolite frameworks are proposed to be of strong potential drug delivery vehicle for the treatment of gastrointestinal cancer. Graphical abstract

show abstract

“…Many studies have been conducted to synthesize and develop nanomaterials used for advanced drug delivery systems, especially hydrophobic medicines which cannot be prescribed without a controlled dose program . In this regard, the application of polymer materials is strongly recommended due to their versatility, suitable physical chemistry characteristics, and ability to conjugate with drug molecules as well as acceptable rate of degradation under appropriate biological conditions, preserving the concentration of drugs in their therapeutic window …”

Section: Introductionmentioning

confidence: 99%

“…Moreover, the continuous use of 5‐FU to compensate the concentration fluctuations and to achieve the effective therapeutic doses can have chronic toxic effects on gastrointestinal pathway, bone marrow, and nervous system as well as skin reactions during the course of the therapy. Therefore, the drug concentration not only must be in its therapeutic dosage, but it should be also below the toxicity threshold . By considering these shortcomings, it seems that choosing an appropriate polymer carrier for transferring 5‐FU will be an inspiring solution for reducing the systemic adverse side effects and achieving safer treatment processes …”

Section: Introductionmentioning

confidence: 99%

Poly (methacrylic acid)‐based molecularly imprinted polymer nanoparticles containing 5‐fluourouracil used in colon cancer therapy potentially

Madadian-Bozorg

Zahedi

Shamsi

et al. 2018

Polymers for Advanced Techs

View full text Add to dashboard Cite

The objective of this work was to synthesize molecularly imprinted polymer (MIP) nanoparticles based on methacrylic acid (MAA) monomer with a high selectivity against an anti-cancer drug, 5-fluorouracil (5-FU), as a template. In this case, the nanoparticles were prepared via precipitation polymerization in the presence of ethylene glycol dimethacrylate as cross-linker and azobisisobutyronitrile as initiator. Besides, 3 independent variables including MAA: 5-FU molar ratio (X 1 ), temperature (X 2 ), and time (X 3 ) were investigated utilizing response surface methodology. The scanning electron microscopy and dynamic light scattering resulted the average diameter of approximately 65 nm, and the MIP nanoparticle sample with the imprinting factor of 1.57 was polymerized in optimized conditions as follows: X 1 = 6: 1, X 2 = 60°C, and X 3 = 3 days in acetonitrile as porogenic solvent. Also, Fourier transform infrared spectroscopy (FTIR) and thermogravimetric analysis confirmed the formation of MAA/5-FU complex and lower thermal stability of the washed MIP sample than the unwashed MIP and non-imprinted polymer (NIP) samples, respectively. Moreover, the optimized MIP nanoparticles have more controlled release of 5-FU rather than the NIP sample. Finally, the flow cytometry showed that 5-FU-loaded MIP sample has the highest apoptosis of human colon cancer cell line, HCT-116, after 3 days compared with NIP sample and also the exclusive use of drug.

show abstract

Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives

Cited by 188 publications

References 66 publications

<p>Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD</p>

<p>Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD</p>

Different zeolite systems for colon cancer therapy: monitoring of ion release, cytotoxicity and drug release behavior

Poly (methacrylic acid)‐based molecularly imprinted polymer nanoparticles containing 5‐fluourouracil used in colon cancer therapy potentially

Contact Info

Product

Resources

About